19
Apr

Edinburgh, UK, 19th April 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders.

16
Mar

Edinburgh, UK, 16th March 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce it has been granted a key patent (EP2668277B1) by the European Patent Office, protecting PromPT™ - its proprietary synthetic promoter development platform.

04
Jan

Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.

07
Dec

Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to expand the research collaboration with Adverum Biotechnologies that began in December 2015.

05
Dec

Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a collaboration with Sartorius Stedim Cellca (Cellca) to evaluate and test its customised synthetic promoters with Sartorius’ proprietary mammalian production cell platform. The goal of the programme is to reduce timelines and increase yields in the development of stable cell lines for the production of biopharmaceuticals.

Pages